EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines)

被引:492
作者
Madersbacher, S
Alivizatos, G
Nordling, J
Sanz, CR
Emberton, M
de la Rosette, JJMCH
机构
[1] Univ Amsterdam, AMC Univ Hosp, Dept Urol, NL-1100 DE Amsterdam, Netherlands
[2] Donauspital, Dept Urol & Androl, Vienna, Austria
[3] Sismanoglio Hosp, Athens Med Sch, Urol Dept 2, Athens, Greece
[4] Univ Copenhagen, Herlev Hosp, Dept Urol, Copenhagen, Denmark
[5] Univ Zaragoza, Hosp Miguel Servet, Dept Urol, Zaragoza, Spain
[6] UCL Royal Free & Univ Coll Med Sch, Inst Urol, London, England
关键词
BPH; prostate; guidelines; treatment; diagnosis;
D O I
10.1016/j.eururo.2004.07.016
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: To provide the first update of the EAU guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO). Methods: A systematic literature review was conducted based on the results of a MEDLINE(R) search concentrating on the years 1999-2003. In combination with expert opinions recommendations were made on the usefulness of diagnostic tests, therapeutic options and follow-up. Results: During initial assessment the following tests are recommended: medical history, physical examination including digital-rectal examination, International Prostate Symptom Score, urinalysis, serum creatinine and prostate specific antigen measurement, uroflowmetry and post-void residual volume. All other tests are optional or not recommended. Aim of treatment is to improve LUTS and quality of life and to prevent severe BPE-related complications. Development of a 5alpha-reductase type I and II inhibitor and the data of the MTOPS trial providing scientific evidence for a combination therapy were the most significant innovations since the first version. Finally a more detailed knowledge on the natural history with identification of several risk factors for progression is the basis for a risk-profile orientated (preventive) therapy. Conclusions: Updated recommendations for assessment, treatment, and follow-up of patients with LUTS due to BPO are presented. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:547 / 554
页数:8
相关论文
共 37 条
  • [1] The progression of benign prostatic hyperplasia: Examining the evidence and determining the risk
    Anderson, JB
    Roehrborn, CG
    Schalken, JA
    Emberton, M
    [J]. EUROPEAN UROLOGY, 2001, 39 (04) : 390 - 398
  • [3] Could self-management challenge pharmacotherapy as a longterm treatment for uncomplicated lower urinary tract symptoms?
    Brown, CT
    Emberton, M
    [J]. CURRENT OPINION IN UROLOGY, 2004, 14 (01) : 7 - 12
  • [4] A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia
    Bruskewitz, R
    Issa, MM
    Roehrborn, CG
    Naslund, MJ
    Perez-Marrero, R
    Shumaker, BP
    Oesterling, JE
    [J]. JOURNAL OF UROLOGY, 1998, 159 (05) : 1588 - 1593
  • [5] Chapple C R, 2001, Curr Opin Urol, V11, P9, DOI 10.1097/00042307-200101000-00002
  • [6] Side-firing neodymium: YAG laser prostatectomy
    Costello, AJ
    Kabalin, JN
    [J]. EUROPEAN UROLOGY, 1999, 35 (02) : 138 - 146
  • [7] Transurethral microwave thermotherapy: The gold standard for minimally invasive therapies for patients with benign prostatic hyperplasia?
    De La Rosette, JJMCH
    Laguna, MP
    Gravas, S
    De Wildt, MJAM
    [J]. JOURNAL OF ENDOUROLOGY, 2003, 17 (04) : 245 - 251
  • [8] EAU guidelines on benign prostatic hyperplasia (BPH)
    de la Rosette, JJMCH
    Alivizatos, G
    Madersbacher, S
    Perachino, M
    Thomas, D
    Desgrandchamps, F
    De Wildt, M
    [J]. EUROPEAN UROLOGY, 2001, 40 (03) : 256 - 263
  • [9] Clinical results of microwave thermotherapy for benign prostatic hyperplasia
    De Wildt, MJAM
    Wagrell, L
    Larson, TR
    Eliasson, T
    [J]. JOURNAL OF ENDOUROLOGY, 2000, 14 (08) : 651 - 656
  • [10] Comparison of a phytotherapeutic agent (Permixon) with an α-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia:: A 1-year randomized international study
    Debruyne, F
    Koch, G
    Boyle, P
    Da Silva, FC
    Gillenwater, JG
    Hamdy, FC
    Perrin, P
    Teillac, P
    Vela-Navarrete, R
    Raynaud, JP
    [J]. EUROPEAN UROLOGY, 2002, 41 (05) : 497 - 506